Julia Nilsson, Research Associate at InfiCure Bio, will be presenting at the Keystone Symposium: "Integrated Pathways of Disease in NASH and NAFLD" in Santa Fee January 20-24 2019. Julia will present new data on the [...]

The CEO of InfiCure Bio was one of 28 Expert Speakers at the Anti-Fibrotic Drug Development Summit held in Boston November 27-29 2018. InfiCure Bio was presenting new data on the unique NIF mouse as [...]

InfiCure Bio is present at the 2nd NASH summit in Europe held in Frankfurt. We are presenting our new models for NASH, the NIF-HFD mouse and the MEL-HFD mouse. InfiCure did also moderate the round [...]

InfiCure Bio is nominated in the category "Spin-off company of the year" at UmeåGalan 2018 and we are very happy and excited about it. UmeåGalan will be held on November 8th and this is an [...]

We are happy to announce that a new publication on the N-IF mouse is published in Plos One. The publication shows treatment of liver fibrosis in the N-IF mouse and the results verify that the fibrosis, which [...]

We are proud to announce that InfiCure Bio has signed a collaboration agreement with the global biotech company CSL (https://www.csl.com).   The signing of the contract entails collaboration between InfiCure Bio and CSL in testing [...]